Antihypertensive agents

Hypertension in CKD Markets: Diuretics, RAS Blockade, B-Blockers, Calcium Channel Blockers - Global Size, Share, Outlook, and Opportunity Analysis, 2020-2021 & 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 26, 2021
Health, Pharmaceutical, Chemical compounds, Antihypertensive agents, Drugs, Chemistry, Carboxylic acids, Combination drugs, Sacubitril/valsartan, Sacubitril, Valsartan, Novartis, Angiotensin II receptor blocker

The "Hypertension in CKD Market, by Drug Class, By Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hypertension in CKD Market, by Drug Class, By Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • For instance, in 2018, Novartis International AG announced positive results for Entresto (sacubitril/valsartan).
  • According to the clinical trials conducted by the company, it was found that Entresto (sacubitril/valsartan) helped to preserve kidney function in patients suffering from cardiovascular diseases.
  • The increasing number of patients undergoing dialysis treatment is expected to drive growth of the global hypertension in CKD market.

Quantum Genomics Announces the Publication of New Scientific Article in Biomedicine & Pharmacotherapy Which Further Strengthens its Phase III Development Plan in Difficult to Treat and Resistant Hypertension

Retrieved on: 
Wednesday, May 19, 2021
Antihypertensive agents, Diuretics, Drugs, Hypertension, ACE inhibitors, Prodrugs, Hydrochlorothiazide, Enalapril/hydrochlorothiazide

The reported data demonstrate that the hypotensive effect induced in hypertensive DOCA-salt rat with a once-daily treatment consisting of firibastat associated with enalapril and hydrochlorothiazide is significantly greater than that induced by firibastat alone or by bitherapy enalapril/hydrochlorothiazide.

Key Points: 
  • The reported data demonstrate that the hypotensive effect induced in hypertensive DOCA-salt rat with a once-daily treatment consisting of firibastat associated with enalapril and hydrochlorothiazide is significantly greater than that induced by firibastat alone or by bitherapy enalapril/hydrochlorothiazide.
  • \xe2\x80\x9cThese data follow those already obtained from studies of firibastat as monotherapy and further reinforce our strategy of using firibastat to improve blood pressure control in hypertensive patients who are difficult to treat or resistant.\xe2\x80\x9d\nQuantum Genomics is a biopharmaceutical company specializing in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI).
  • Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain.
  • The company relies on 20 years of academic research from the Paris-Descartes University and the laboratory directed by Dr. Catherine Llorens-Cortes at the Coll\xc3\xa8ge de France (French National Institute of Health and Medical Research (INSERM) / the Scientific Centre for National Research (CNRS)).

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Retrieved on: 
Tuesday, February 16, 2021
Antihypertensive agents, Medical specialties, Clinical medicine, Drugs, Carboxylic acids, Sacubitril/valsartan, Heart failure, Valsartan, Sacubitril, Neprilysin, Angiotensin II receptor blocker, Angiotensin

FortiHFy includes trials across the spectrum of heart failure, such as PARADIGM-HF, PIONEER-HF, TRANSITION, PROVE-HF, PARAGON-HF and PARAMOUNT.

Key Points: 
  • FortiHFy includes trials across the spectrum of heart failure, such as PARADIGM-HF, PIONEER-HF, TRANSITION, PROVE-HF, PARAGON-HF and PARAMOUNT.
  • Entresto (sacubitril/valsartan) is a prescription medicine to treat adults with long-lasting (chronic) heart failure to help reduce the risk of death and hospitalization.
  • Patients should talk to their doctor about other ways to treat heart failure if they plan to become pregnant.
  • 2010;303(21):2141-2147. doi:10.1001/jama.2010.748
    Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure.

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Retrieved on: 
Tuesday, February 16, 2021
Circulatory system, Cardiovascular system, Medical specialties, Heart diseases, Antihypertensive agents, Combination drugs, Sacubitril/valsartan, Organ failure, Heart failure with preserved ejection fraction, Heart failure, Ejection fraction, Angiotensin

For the first time, there is a treatment with benefit for patients diagnosed with guideline-defined heart failure that includes both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF)1-3.

Key Points: 
  • For the first time, there is a treatment with benefit for patients diagnosed with guideline-defined heart failure that includes both those with heart failure with reduced ejection fraction (HFrEF) and many with heart failure with preserved ejection fraction (HFpEF)1-3.
  • Approximately 6 million Americans are living with chronic heart failure (CHF)4.
  • In the United States, Entresto is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure1.
  • Accessed July 2019. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Info...
    Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure.

Monopar Announces Issuance of New Patents Broadening Protections For Phase 2b/3 Clinical-Stage Lead Product Candidate Validive®

Retrieved on: 
Monday, November 9, 2020
Medicine, Clinical medicine, Medical specialties, Antihypertensive agents, Cancer treatments, Mucositis, Clonidine, Chemotherapy, Adverse effect, Patent

10,675,271, provide claims covering Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy.

Key Points: 
  • 10,675,271, provide claims covering Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy.
  • These recently issued patents broaden the patent protection for the use of Validive in cancer patients, said Andrew Mazar, PhD, Chief Scientific Officer of Monopar.
  • These patents expand the potential use of Validive beyond the earlier allowed claims for the prevention of oral mucositis in patients receiving chemoradiotherapy.
  • The recently issued patents would provide protection should Monopar determine in the future to conduct additional Validive development activities related to adverse side effects of chemotherapy beyond OPC.

Quantum Genomics Announces Interim Analysis from Study of Firibastat in Renal Failure Patients

Retrieved on: 
Wednesday, May 6, 2020
Comorbidity, Chemical compounds, Kidney, Chloroarenes, Organic compounds, Organ systems, Calcium channel blockers, Dihydropyridines, Antihypertensive agents

The pharmacokinetic parameters obtained and the good tolerance of the product suggest that a simple dose adjustment could allow the use of firibastat in patients with chronic renal failure.

Key Points: 
  • The pharmacokinetic parameters obtained and the good tolerance of the product suggest that a simple dose adjustment could allow the use of firibastat in patients with chronic renal failure.
  • These interim results provide important insights since we know now how to adapt the firibastat dose to enroll patients with severe to end-stage renal failure in our clinical studies, said Bruno Besse Chief Medical Officer of Quantum Genomics.
  • this will confirm that firibastat could be used to treat heart failure patients and treatment-resistant hypertensive patients even in the case of concomitant renal dysfunction, including end-stage, where very limited options are available.
  • Jean-Philippe Milon, Chief Executive Officer of Quantum Genomics commented: Renal failure is a common comorbidity in patients with hypertension and with heart failure.

Insights on the Worldwide Antihypertensive Drugs Industry to 2026 - Players Include Pfizer, Takeda Pharmaceutical & AstraZeneca Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, April 6, 2020
Health, Pharmaceutical, Antihypertensive agents, Beta blocker, Antihypertensive drug, Hypertension, Calcium channel blocker, Cardiovascular system, Circulatory system, Medicine

The global antihypertensive market accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026.

Key Points: 
  • The global antihypertensive market accounted for $22,557 million in 2018, and is expected to reach $28,797 million by 2026, registering a CAGR of 3.1% from 2019 to 2026.
  • Antihypertensive drugs are employed for the treatment of patients suffering from hypertension.
  • Therefore, the treatment of this medical condition requires early diagnosis and management by the use of antihypertensive drugs.
  • Some of the antihypertensive drugs available in the market include beta blockers, calcium channel blockers, and vasodilators.

Unhealthy Lifestyle Choices and Disturbed Work Life Balance to Lead Increased Sales of Antihypertensive Drugs Market; Valuation to Rise Up to US$33.9 Bn by 2027, Finds TMR

Retrieved on: 
Wednesday, March 11, 2020
Hypertension, Blood pressure, Antihypertensive agents, Medicine, Branches of biology, Causes of death

TMR has recently published a new research about the market and provides an in-depth information about the inner working dynamics of the global antihypertensive drugs market.

Key Points: 
  • TMR has recently published a new research about the market and provides an in-depth information about the inner working dynamics of the global antihypertensive drugs market.
  • With the given rate of growth, the valuation of the market will rise up to around US$33.9 Bn by the end of 2027.
  • "In the last few decades, a considerable amount of research has been done for the development of new therapeutics and effective antihypertensive drugs.
  • In spite of considerable developments in genomics and their clinical applications, landmark developments in the global antihypertensive drugs market are still achieved slowly.

Unhealthy Lifestyle Choices and Disturbed Work Life Balance to Lead Increased Sales of Antihypertensive Drugs Market; Valuation to Rise Up to US$33.9 Bn by 2027, Finds TMR

Retrieved on: 
Wednesday, March 11, 2020
Hypertension, Blood pressure, Antihypertensive agents, Medicine, Branches of biology, Causes of death

TMR has recently published a new research about the market and provides an in-depth information about the inner working dynamics of the global antihypertensive drugs market.

Key Points: 
  • TMR has recently published a new research about the market and provides an in-depth information about the inner working dynamics of the global antihypertensive drugs market.
  • With the given rate of growth, the valuation of the market will rise up to around US$33.9 Bn by the end of 2027.
  • "In the last few decades, a considerable amount of research has been done for the development of new therapeutics and effective antihypertensive drugs.
  • In spite of considerable developments in genomics and their clinical applications, landmark developments in the global antihypertensive drugs market are still achieved slowly.

Antihypertensive Drugs Market to Garner $28.79 Bn, Globally, by 2026 at 3.1% CAGR, Says Allied Market Research

Retrieved on: 
Wednesday, January 15, 2020
Antihypertensive agents, Blood pressure, Hypertension, Antihypertensive drug, Medicine, Clinical medicine, Medical specialties

According to the report, the global antihypertensive drugs industry was pegged at $22.56 billion in 2018 and is projected to reach $28.79 billion by 2026, registering a CAGR of 3.1% from 2019 to 2026.

Key Points: 
  • According to the report, the global antihypertensive drugs industry was pegged at $22.56 billion in 2018 and is projected to reach $28.79 billion by 2026, registering a CAGR of 3.1% from 2019 to 2026.
  • Rise in the geriatric population, surge in healthcare expenditure, and rise in prevalence of hypertension across the globe drive the growth of the global antihypertensive drugs market.
  • However, the calcium channel blockers segment held the largest share in 2018, contributing to more than one-fourth of the global antihypertensive drugs market, owing to lesser side effects exhibited by these drugs as compared to the other type of antihypertensive drugs.
  • The global antihypertensive drugs market across North America held the largest share in 2018, accounting for more than one-third of the market, owing to the availability of the antihypertensive drugs and rise in prevalence of hypertension due to surge in geriatric population in the region.